tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Raghuram Selvaraju, 1177 are a BUY (93.04%), 84 are a HOLD (6.64%), 4 are a SELL (0.32%).
Analyst Raghuram Selvaraju, currently employed at HC WAINWRIGHT, carries an average stock price target met ratio of 34.43% that have a potential upside of 49.64% achieved within 192 days.
Raghuram Selvaraju’s has documented 2,302 price targets and ratings displayed on 130 stocks. The coverage is on Healthcare, Basic Materials sectors.
Most recent stock forecast was given on BTAI, BioXcel Therapeutics at 05-Mar-2026.
Analyst best performing recommendations are on EVOK (EVOKE PHARMA).
The best stock recommendation documented was for EVOK (EVOKE PHARMA) at 7/18/2016. The price target of $288 was fulfilled within 3 days with a profit of $128.16 (30.8%) receiving and performance score of 102.65.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Sell Since 12-May-2021
$12
$-2.06 (-14.65%)
$7
8 months 11 days ago
(25-Jun-2025)
8/13 (61.54%)
$-4.19 (-25.88%)
55
Buy Since 16-Apr-2021
1 years 8 months 18 days ago
(18-Jun-2024)
10/37 (27.03%)
$101 (102.02%)
298
Sell Since 06-May-2022
2 years 3 months 16 days ago
(20-Nov-2023)
1/3 (33.33%)
$-0.8 (-0.99%)
300
Hold Since 25-Oct-2023
$20
$5.94 (42.25%)
$60
2 years 4 months 11 days ago
(25-Oct-2023)
3/22 (13.64%)
$5.8 (40.85%)
40
Hold Since 04-May-2022
$25
$10.94 (77.81%)
$40
2 years 7 months 17 days ago
(19-Jul-2023)
2/5 (40%)
$3.4 (15.74%)
215
Which stock is Raghuram Selvaraju is most bullish on?
Which stock is Raghuram Selvaraju is most reserved on?
What Year was the first public recommendation made by Raghuram Selvaraju?
